The 2026 ACC/AHA Dyslipidemia Guideline: "Lower, Sooner" and a New CPR Framework
The 2026 ACC/AHA Guideline on the Management of Dyslipidemia (published March 2026, JACC) replaces the 2018 blood-cholesterol guideline and reorganises lipid management around earlier intervention and absolute LDL-C targets — a return to value-based goals over the previous percent-reduction approach. A July 2026 ACC Cardiology magazine practice summary ("Lower Sooner") distils the changes for day-to-day use.
The "CPR" model. Risk assessment is framed as Calculate → Personalize → Reclassify. Clinicians first calculate 10- and 30-year ASCVD risk with the new PREVENT score, then personalize using risk enhancers not captured by PREVENT (premature-ASCVD family history, reproductive risk markers, chronic inflammatory disease, elevated Lp(a) or hsCRP), then reclassify/reassess with coronary artery calcium (CAC) scoring where treatment intensity is uncertain.
Absolute LDL-C goals (reintroduced). For high 10-year PREVENT risk (≥10%): LDL-C <70 mg/dL and non–HDL-C <100 mg/dL. For borderline (3–5%) or intermediate (5–10%) risk: LDL-C <100 mg/dL and non–HDL-C <130 mg/dL.
Lp(a). First ACC/AHA recommendation for universal once-in-a-lifetime Lp(a) measurement, plus genetic cascade screening. Cited thresholds: >125 nmol/L (~1.4-fold) and >250 nmol/L (≥2-fold) higher ASCVD risk. As Lp(a) is genetically stable, one measurement suffices to guide early prevention.
CAC upgraded. CAC scoring moves from Class 2a to Class 1 for risk stratification beyond PREVENT; a CAC of 0 can support deferring statin therapy in a low/intermediate-risk patient without other comorbidities.
Expanded primary prevention. Adults 40–75 with CKD ≥stage 3 or HIV should be started on lipid-lowering therapy regardless of LDL-C or PREVENT score. ApoB is endorsed as a refining measurement in high-risk or established-ASCVD patients even when LDL-C/non–HDL-C are at goal.
Why it matters for central Gujarat patients
South Asians carry a high burden of premature ASCVD and elevated Lp(a). A once-in-a-lifetime Lp(a) test and a "start lower, start younger" LDL-C strategy map directly onto a population that often presents with events a decade earlier than Western cohorts. The CKD/HIV primary-prevention expansion is also relevant given local diabetes-related kidney disease prevalence.
Sources
- ACC Cardiology Magazine, "Prioritizing Health | Lower Sooner: How the 2026 Dyslipidemia Guideline Changes Practice," Jul 1, 2026: https://www.acc.org/Latest-in-Cardiology/Articles/2026/07/01/01/Prioritizing-Health
- Blumenthal R, Morris P, Gaudino M, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. JACC. 2026;87(19):2624-2757: https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
- Wiggins B, et al. 2026 Dyslipidemia Guideline-at-a-Glance. JACC. 2026;87(19):2617-2623: https://www.jacc.org/doi/10.1016/j.jacc.2026.02.4872